


Biden Administration Proposes $35 Billion Coverage for Anti-Obesity Drugs Amid Challenges from Incoming Trump Officials
The Biden administration's rule seeks to allow Medicare and Medicaid coverage for anti-obesity medications, but faces potential opposition and budget concerns.
Overview
On November 26, 2024, the Biden administration proposed a $35 billion plan to cover anti-obesity drugs like Wegovy and Zepbound under Medicare and Medicaid, potentially benefiting millions. However, the rule, requiring Congressional approval, faces skepticism from incoming Trump administration officials, particularly Robert F. Kennedy Jr., who opposes the drugs. While a bipartisan coalition supports the initiative, concerns regarding its high cost and the necessity of price negotiations with manufacturers persist among some lawmakers.
Content generated by AI—learn more or report issue.

Get both sides in 5 minutes with our daily newsletter.
Analysis
Analysis unavailable for this viewpoint.
Articles (24)
Center (13)
History
- 7M4 articles
- 7M4 articles